Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. DSX
2. GNK
3. INTC
4. SPCX
5. III
6. TTEC
7. DAL
8. AWK
9. GZDIF
10. GETY

Go back to Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer
(NASDAQ: APVO) Delayed: 4.67 -0.13 (2.71%)
Previous Close $4.80    52 Week High $4.33 
Open $4.87    52 Week Low $1.80 
Day High $4.87    P/E N/A 
Day Low $4.67    EPS $0.00 
Volume 16,578